Business Context and Reporting Period
This Form 8-K, dated January 6, 2019, reports a material definitive agreement between Vital Therapies, Inc. (the "Registrant") and Immunic AG ("Immunic"). The filing announces a proposed transaction to acquire Immunic, a German biotechnology company, through a share exchange. Upon closing, Vital Therapies intends to change its name to Immunic, Inc. and effect a reverse stock split.
Key Financial Metrics and Transaction Terms
- Transaction Structure: Shareholders of Immunic will exchange their shares for Vital Therapies common stock based on an Exchange Ratio, subject to adjustment for pre-closing issuances and Vital Therapies' net cash balance.
- Pro Forma Ownership: Following the transaction, current Vital Therapies stockholders are expected to own approximately 11% of the combined company, while current Immunic shareholders are expected to own approximately 89%.
- Concurrent Financing: Immunic shareholders have agreed to purchase approximately €26.3 million of Immunic common stock prior to the transaction closing.
- Termination Fees: If the agreement is terminated under specified circumstances, Vital Therapies may owe Immunic $500,000, and Immunic may owe Vital Therapies $2,000,000.
- Financial Data: The filing text does not provide specific revenue, profit, cash flow, or debt figures for either entity.
Material Changes and Conditions
The transaction represents a fundamental change in the Registrant's business operations and corporate identity. Key conditions precedent to closing include:
- Approval by Vital Therapies stockholders of the transaction and an amendment to the certificate of incorporation to effect a reverse stock split.
- Completion of the concurrent €26.3 million investment by Immunic shareholders.
- Expiration of the termination date of May 30, 2019, without the transaction being consummated.
Upon closing, all outstanding stock options of Vital Therapies will be cancelled and extinguished without consideration.
Outlook, Management Commentary, and Risks
Management Commentary and Outlook: The parties expect the transaction to close in the second quarter of 2019. The new Board of Directors is expected to consist of five members, including four from Immunic's current board and Dr. Duane Nash, President of Vital Therapies. The transaction is intended to qualify as a tax-free reorganization under Section 351(a) of the Internal Revenue Code.
Risks and Contingencies: Forward-looking statements in the filing are subject to risks, including the failure to obtain stockholder approval, inability to satisfy closing conditions (specifically the concurrent financing), and potential legal proceedings. The Exchange Ratio is subject to adjustment, which could impact the final ownership percentages.
Investor Verification Checklist
- Verify the final Exchange Ratio and any adjustments made prior to closing.
- Confirm the successful completion of the €26.3 million concurrent financing by Immunic shareholders.
- Monitor the outcome of the Vital Therapies stockholder vote regarding the transaction and reverse stock split.
- Review the upcoming Form S-4 registration statement for detailed risk factors and financial projections.
- Assess the impact of the cancellation of existing Vital Therapies stock options on employee retention and future compensation plans.